Precipitous release of methyl-CpG binding protein 2 and histone deacetylase 1 from the methylated human multidrug resistance gene (MDR1) on activation

Molecular and Cellular Biology

Volumn 22, Issue 6, 2002, Pages 1844-1857

  El Osta, Assam ^a   Kantharidis, Phillip ^a   Zalcberg, John R ^a   Wolffe, Alan P ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; DNA BINDING PROTEIN; DNA METHYLTRANSFERASE; GLYCOPROTEIN P; HISTONE DEACETYLASE; HISTONE H3; HISTONE H4; ISOENZYME; METHYL CPG BINDING PROTEIN 2; TRICHOSTATIN A; UNCLASSIFIED DRUG;

ARTICLE; CHROMATIN; CHROMATIN STRUCTURE; CONTROLLED STUDY; CPG ISLAND; DEACETYLATION; DNA METHYLATION; ENZYME ACTIVITY; ENZYME INHIBITION; GENE; GENE ACTIVATION; GENE REPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; MOLECULAR RECOGNITION; MULTIDRUG RESISTANCE GENE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN ASSEMBLY; PROTEIN MODIFICATION; PROTEIN SECRETION; REGULATORY MECHANISM; REPRESSOR GENE; STRUCTURE ACTIVITY RELATION; TRANSCRIPTION REGULATION;

ACETYLATION; ANIMALS; CELL LINE; CHROMATIN; CHROMOSOMAL PROTEINS, NON-HISTONE; CPG ISLANDS; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; ENDODEOXYRIBONUCLEASES; ENZYME INHIBITORS; GENE SILENCING; GENES, MDR; HISTONE DEACETYLASES; HUMANS; LEUKEMIA, T-CELL; METHYL-CPG-BINDING PROTEIN 2; OOCYTES; PROMOTER REGIONS (GENETICS); REPRESSOR PROTEINS; TRANSCRIPTION, GENETIC; XENOPUS LAEVIS;

EID: 0036182132     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.22.6.1844-1857.2002     Document Type: Article

References (66)

1. Selective recognition of methylated lysine 9 on histone H3 by the HP1 chromo domain
2. Nucleosomal structural changes due to acetylation
3. Gene silencing. Methylation meets acetylation
4. DNA methylation inhibits transcription indirectly via a methyl-CpG binding protein
5. Repression of genes by DNA methylation depends on CpG density and promoter strength: Evidence for involvement of a methyl-CpG binding protein
6. Synergy of demethylalion and histone deacelylase inhibition in the re-expression of genes silenced in cancer
7. High sensitivity mapping of methylated cytosines
8. Acetylated histones are associated with FMR1 in normal but not fragile X-syndrome cells
9. Ordered recruitment of transcription and chromatin remodeling factors to a cell cycle- and developmentally regulated promoter
10. A component of the transcriptional repressor MeCP1 shares a motif with DNA methyltransferase and HRX proteins
11. Synergism of Xist RNA, DNA methylation, and histone hypoacetylation in maintaining X chromosome inactivation
12. Demethylation of the human MDR1 5′ region accompanies activation of P-glycoprotein expression in a HL60 multidrug resistant subline
13. DNA methylation models histone acetylation
14. Absolute quantitation of MDR1 transcripts using heterologous DNA standards - Validation of the competitive RT-PCR (CRT-PCR) approach
15. Developmentally dynamic histone acetylation pattern of a tissue-specific chromatin domain
16. DNA methyltransferase dnmt1 associates with histone deacetylase activity
17. DNA methylation is linked to deacetylation of histone H3, but not H4, on the imprinted genes Snrpn and U2af1-rs1
18. Identification and characterization of a family of mammalian methyl-CpG binding proteins
19. The thymine glycosylase MBD4 can bind to the product of deamination at methylated CpG sites
20. Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B
21. The inactive X chromosome in female mammals is distinguished by a lack of histone H4 acetylation, a cytogenetic marker for gene expression
22. Transcriptional regulation of the MDR1 gene by histone acetyltransferase and deacetylase is mediated by NF-Y
23. Cancer epigenetics comes of age
24. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription
25. MeCP2 driven transcriptional repression in vitro: Selectivity for methylated DNA, action at a distance and contacts with the basal transcription machinery
26. Altered methylation of the human MDR1 promoter is associated with acquired multidrug resistance
27. Regulation of MDR1 gene expression: Emerging concepts
28. Histone acetylation and X inactivation
29. Analysis of DNA methylation of the 5′ region of the deoxycytidine kinase gene in CCRF-CEM-sensitive and cladribine (CdA)- and 2-chloro-2′-arabino-fluoro-2′-deoxyadenosine (CAFdA)-resistant cells
30. Purification, sequence, and cellular localization of a novel chromosomal protein that binds to methylated DNA
31. Methylation-mediated proviral silencing is associated with MeCP2 recruitment and localized histone H3 deacetylation
32. Crystal structure of the nucleosome core particle at 2.8 A resolution
33. Selective association of the methyl-CpG binding protein MBD2 with the silent p14/p16 locus in human neoplasia
34. Chicken minichromosomes are hyperacetylated, early replicating and gene rich
35. Identification of a mammalian protein that binds specifically to DNA containing methylated CpGs
36. Characterization of MeCP2, a vertebrate DNA binding protein with affinity for methylated DNA
37. The corepressor N-CoR and its variants RIP13a and RIP13Delta1 directly interact with the basal transcription factors TFIIB, TAFII32 and TAFII70
38. Hypomethylation status of CpG sites at the promoter region and overexpression of the human MDR1 gene in acute myeloid leukemias
39. Dissection of the methyl-CpG binding domain from the chromosomal protein MeCP2
40. DNA methylation specifies chromosomal localization of MeCP2
41. MeCP2 is a transcriptional repressor with abundant binding sites in genomic chromatin
42. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex
43. MBD2 is a transcriptional repressor belonging to the MeCP1 histone deacetylase complex
44. DNA methylation and chromatin modification
45. Active repression of methylated genes by the chromosomal protein MBD1
46. The C-terminal domain of Sin1 interacts with the SWI-SNF complex in yeast
47. ATP-dependent chromatin remodeling: Going mobile
48. Investigation of the substrate spectrum of the human mismatch-specific DNA N-glycosylase MED1 (MBD4): Fundamental role of the catalytic domain
49. A transient histone hyper-acetylation signal marks nucleosomes for remodeling at the PHO8 promoter in vivo
50. DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters
51. DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication foci
52. Genomic targeting of methylated DNA: Influence of methylation on transcription, replication, chromatin structure, and histone acetylation
53. Purification and characterization of mSin3A-containing Brg1 and hBrm chromatin remodeling complexes
54. MBD2-MBD3 complex binds to hemi-methylated DNA and forms a complex containing DNMT1 at the replication foci in late S phase
55. Recent progress in P-glycoprotein research
56. Histone acetylation: Influence on transcription, nucleosome mobility and positioning, and linker histone-dependent transcriptional repression
57. Histone deacetylase directs the dominant silencing of transcription in chromatin: Association with MeCP2 and the Mi-2 chromodomain SWI/SNF ATPase
58. A multiple subunit Mi-2 bistone deacetylase from Xenopus laevis cofractionates with an associated Snf2 superfamily ATPase
59. Mi-2 complex couples DNA methylation to chromatin remodeling and histone deacetylation
60. Histone underacetylation is an ancient component of mammalian X chromosome inactivation
61. Expression of MDR1 and mrp in the normal B-cell homologue of B-cell chronic lymphocytic leukaemia
62. Diversity and specialization of mammalian SWI/SNF complexes
63. Purification and biochemical heterogeneity of the mammalian SWI-SNF complex
64. Chicken MAR-binding protein ARBP is homologous to rat methyl-CpG-binding protein MeCP2
65. Transcriptional repression by the SMRT-mSin3 corepressor: Multiple interactions, multiple mechanisms, and a potential role for TFIIB
66. Cellular and karyotypic characterization of two doxorubicin resistant cell lines isolated from the same parental human leukemia cell line